JP2013529070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529070A5 JP2013529070A5 JP2013505070A JP2013505070A JP2013529070A5 JP 2013529070 A5 JP2013529070 A5 JP 2013529070A5 JP 2013505070 A JP2013505070 A JP 2013505070A JP 2013505070 A JP2013505070 A JP 2013505070A JP 2013529070 A5 JP2013529070 A5 JP 2013529070A5
- Authority
- JP
- Japan
- Prior art keywords
- scaffold
- seq
- multimeric
- multimeric scaffold
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000178 monomer Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 4
- 108700012411 TNFSF10 Proteins 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32370810P | 2010-04-13 | 2010-04-13 | |
| US61/323,708 | 2010-04-13 | ||
| PCT/US2011/032188 WO2011130328A1 (en) | 2010-04-13 | 2011-04-12 | Trail r2-specific multimeric scaffolds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529070A JP2013529070A (ja) | 2013-07-18 |
| JP2013529070A5 true JP2013529070A5 (enExample) | 2014-04-10 |
| JP6041799B2 JP6041799B2 (ja) | 2016-12-14 |
Family
ID=44799000
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505070A Active JP6041799B2 (ja) | 2010-04-13 | 2011-04-12 | Ｔｒａｉｌｒ２特異的多量体足場 |
| JP2013505069A Pending JP2013523179A (ja) | 2010-04-13 | 2011-04-12 | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505069A Pending JP2013523179A (ja) | 2010-04-13 | 2011-04-12 | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9212231B2 (enExample) |
| EP (2) | EP2560684A4 (enExample) |
| JP (2) | JP6041799B2 (enExample) |
| KR (2) | KR20130056870A (enExample) |
| CN (2) | CN102834114A (enExample) |
| AU (2) | AU2011240624B2 (enExample) |
| BR (1) | BR112012026003B1 (enExample) |
| CA (2) | CA2796010C (enExample) |
| ES (1) | ES2755398T3 (enExample) |
| MX (1) | MX341119B (enExample) |
| RU (1) | RU2628699C2 (enExample) |
| SG (2) | SG184185A1 (enExample) |
| WO (2) | WO2011130328A1 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005056764A2 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
| JP5537946B2 (ja) | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬 |
| JP2011517314A (ja) | 2008-02-14 | 2011-06-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬 |
| PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| CA2796010C (en) * | 2010-04-13 | 2020-05-12 | Medimmune, Llc | Trail r2-specific multimeric scaffolds |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| US9347058B2 (en) | 2011-05-17 | 2016-05-24 | Bristol-Myers Squibb Company | Methods for the selection of binding proteins |
| KR20220116585A (ko) | 2011-10-11 | 2022-08-23 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| PL2776460T3 (pl) | 2011-11-08 | 2018-10-31 | Umc Utrecht Holding B.V. | Białko fuzyjne zawierające interleukinę 4 i interleukinę 10 |
| HUE043482T2 (hu) | 2012-09-13 | 2019-08-28 | Bristol Myers Squibb Co | Miosztatint megkötõ fibronektin alapú váz domén proteinek |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP2953968B1 (en) | 2013-02-06 | 2018-07-25 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| EP2956468B1 (en) | 2013-02-12 | 2020-06-10 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| PT2970473T (pt) | 2013-03-14 | 2017-10-26 | Bristol Myers Squibb Co | Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização |
| US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| KR20160067966A (ko) | 2013-10-14 | 2016-06-14 | 얀센 바이오테크 인코포레이티드 | 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자 |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| SG11201607818WA (en) | 2014-03-20 | 2016-10-28 | Bristol Myers Squibb Co | Stabilized fibronectin based scaffold molecules |
| EP3129401B1 (en) | 2014-03-20 | 2019-06-12 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
| WO2015148269A2 (en) * | 2014-03-24 | 2015-10-01 | Medimmune, Llc | Stabilized tnfn3 scaffold proteins |
| NO2776305T3 (enExample) | 2014-04-23 | 2018-01-27 | ||
| JP6655074B2 (ja) * | 2014-06-20 | 2020-02-26 | ジェネンテック， インコーポレイテッド | シャガシンに基づく足場組成物、方法及び使用 |
| US20170304460A1 (en) | 2014-10-01 | 2017-10-26 | Medimmune, Llc | Method of conjugating a polypeptide |
| US11229713B2 (en) | 2014-11-25 | 2022-01-25 | Bristol-Myers Squibb Company | Methods and compositions for 18F-radiolabeling of biologics |
| CN107428817B (zh) | 2015-03-12 | 2022-07-12 | 免疫医疗有限责任公司 | 纯化白蛋白融合蛋白的方法 |
| WO2016154530A1 (en) * | 2015-03-26 | 2016-09-29 | Duke University | Targeted therapeutic agents comprising multivalent protein-biopolymer fusions |
| WO2016179518A2 (en) * | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
| WO2017024182A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| WO2017048709A1 (en) | 2015-09-14 | 2017-03-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Generating recominant affinity reagents with arrayed targets |
| EP3353198B1 (en) * | 2015-09-23 | 2020-06-17 | Bristol-Myers Squibb Company | Glypican-3binding fibronectin based scafflold molecules |
| ES2781207T3 (es) | 2015-09-23 | 2020-08-31 | Bristol Myers Squibb Co | Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida |
| KR20180100302A (ko) * | 2015-10-23 | 2018-09-10 | 우니베르지태트 트벤테 | 인테그린 결합 펩티드 및 그의 용도 |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| AU2017248264B2 (en) | 2016-04-07 | 2020-01-30 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| CN105802970A (zh) * | 2016-05-30 | 2016-07-27 | 东北师范大学 | 靶向沉默Gβ1的shRNA |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| AU2017281083B2 (en) | 2016-06-21 | 2022-01-27 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
| WO2018053201A1 (en) | 2016-09-14 | 2018-03-22 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
| EP3515928B1 (en) | 2016-09-23 | 2026-01-28 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| BR112019012154A2 (pt) | 2016-12-14 | 2019-11-12 | Janssen Biotech, Inc. | domínios do tipo iii da fibronectina de ligação a cd8a |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| US10787499B2 (en) * | 2017-02-13 | 2020-09-29 | Regents Of The University Of Minnesota | EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| US11491206B1 (en) | 2018-02-13 | 2022-11-08 | Duke University | Compositions and methods for the treatment of trail-resistant cancer |
| US11680091B2 (en) | 2018-02-23 | 2023-06-20 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type III (FN3) monobodies |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3955955B1 (en) | 2019-04-19 | 2025-02-26 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| WO2021009692A1 (en) | 2019-07-15 | 2021-01-21 | Medimmune Limited | Tripartite systems for protein dimerization and methods of use |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| WO2021076546A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN111217903B (zh) * | 2020-02-25 | 2022-11-15 | 芜湖天明生物技术有限公司 | 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用 |
| EP4110407A1 (en) | 2020-02-28 | 2023-01-04 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
| EP4126241A1 (en) | 2020-03-27 | 2023-02-08 | Novartis AG | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| CN111944204B (zh) * | 2020-07-24 | 2022-03-08 | 南京理工大学 | 一种Fe3O4磁性细菌纤维素及其制备方法 |
| WO2022063887A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
| IL301332A (en) | 2020-09-23 | 2023-05-01 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of autoantibody-mediated conditions |
| CA3192748A1 (en) | 2020-09-23 | 2022-03-31 | Oskar SMRZKA | Compound for increasing efficacy of viral vectors |
| US20230381334A1 (en) | 2020-09-23 | 2023-11-30 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| AR123581A1 (es) | 2020-09-23 | 2022-12-21 | Ablevia Biotech Gmbh | Compuesto para el secuestro de anticuerpos anti peg no deseables en un paciente |
| US20230381328A1 (en) | 2020-09-24 | 2023-11-30 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of myasthenia gravis |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| AU2021374083A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| IL307582A (en) | 2021-04-14 | 2023-12-01 | Aro Biotherapeutics Company | CD71-binding domains of the fibronectin type |
| US12239710B2 (en) | 2021-04-14 | 2025-03-04 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CA3246627A1 (en) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | COMPOUND FOR INCREASING THE EFFECTIVENESS OF ONCOLYTIC VIRUSES |
| KR102459313B1 (ko) * | 2022-04-11 | 2022-10-26 | 주식회사 대영방재산업 | 내구성이 개선된 소방용 수격 흡수기 |
| WO2024261323A1 (en) | 2023-06-23 | 2024-12-26 | Astrazeneca Ab | Molecular switches |
| WO2025125630A1 (en) | 2023-12-15 | 2025-06-19 | Medimmune Limited | Method for bioprotac design |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0781297A4 (en) | 1994-09-16 | 1999-05-19 | Scripps Research Inst | CYTOTACTIN DERIVATIVES THAT PROMOTE NEURONAL CONNECTIONS AND NEURITE GROWTH AND PROCESS YOUR PRODUCTION AND APPLICATION |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6160089A (en) | 1998-07-08 | 2000-12-12 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| DE69901569T2 (de) * | 1998-08-28 | 2002-12-19 | Genentech, Inc. | Humane antikörper gegen faktor ix/ixa |
| US7115396B2 (en) * | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1137941B2 (en) | 1998-12-10 | 2013-09-11 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| ES2564161T3 (es) * | 2000-07-11 | 2016-03-18 | Research Corporation Technologies, Inc | Polipéptidos de anticuerpos artificiales |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| EP1495128B1 (en) | 2002-03-29 | 2014-05-07 | Genencor International, Inc. | Ehanced protein expression in bacillus |
| WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
| EP2500032A1 (en) | 2002-06-24 | 2012-09-19 | Genentech, Inc. | APO-2 ligand/trail variants and uses thereof |
| WO2005056764A2 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
| US20080206229A1 (en) | 2003-12-12 | 2008-08-28 | Koichiro Ono | Modified Antibodies Recognizing Receptor Trimers or Higher Multimers |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| UA97096C2 (ru) * | 2005-08-31 | 2012-01-10 | Емджен Інк. | Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2) |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| EP1989529A4 (en) | 2006-02-13 | 2010-09-01 | Agency Science Tech & Res | PROCESS FOR PROCESSING A BIOLOGICAL AND / OR CHEMICAL SAMPLE |
| CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| JP5537946B2 (ja) | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬 |
| AU2008287426B2 (en) | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| RU2010121967A (ru) * | 2007-10-31 | 2011-12-10 | Медиммун, Ллк (Us) | Белковые каркасные структуры |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| WO2010042890A2 (en) | 2008-10-10 | 2010-04-15 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
| BRPI0919881B1 (pt) * | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| US20120270797A1 (en) | 2009-08-13 | 2012-10-25 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| CA2796010C (en) * | 2010-04-13 | 2020-05-12 | Medimmune, Llc | Trail r2-specific multimeric scaffolds |
-
2011
- 2011-04-12 CA CA2796010A patent/CA2796010C/en active Active
- 2011-04-12 JP JP2013505070A patent/JP6041799B2/ja active Active
- 2011-04-12 SG SG2012070108A patent/SG184185A1/en unknown
- 2011-04-12 KR KR1020127029343A patent/KR20130056870A/ko not_active Withdrawn
- 2011-04-12 EP EP11769477.8A patent/EP2560684A4/en not_active Withdrawn
- 2011-04-12 CN CN2011800187879A patent/CN102834114A/zh active Pending
- 2011-04-12 CN CN201180018796.8A patent/CN102906112B/zh active Active
- 2011-04-12 AU AU2011240624A patent/AU2011240624B2/en active Active
- 2011-04-12 KR KR1020127029323A patent/KR101747991B1/ko active Active
- 2011-04-12 EP EP11769481.0A patent/EP2558495B1/en active Active
- 2011-04-12 ES ES11769481T patent/ES2755398T3/es active Active
- 2011-04-12 WO PCT/US2011/032188 patent/WO2011130328A1/en not_active Ceased
- 2011-04-12 MX MX2012011840A patent/MX341119B/es active IP Right Grant
- 2011-04-12 WO PCT/US2011/032184 patent/WO2011130324A1/en not_active Ceased
- 2011-04-12 AU AU2011240620A patent/AU2011240620A1/en not_active Abandoned
- 2011-04-12 JP JP2013505069A patent/JP2013523179A/ja active Pending
- 2011-04-12 SG SG10201505470QA patent/SG10201505470QA/en unknown
- 2011-04-12 US US13/639,381 patent/US9212231B2/en active Active
- 2011-04-12 CA CA2795325A patent/CA2795325A1/en not_active Abandoned
- 2011-04-12 BR BR112012026003-0A patent/BR112012026003B1/pt active IP Right Grant
- 2011-04-12 RU RU2012147960A patent/RU2628699C2/ru active
- 2011-04-12 US US13/640,057 patent/US20130079280A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012147960A (ru) | Trail r2-специфические мультимерные скаффолды | |
| Lipovšek | Adnectins: engineered target-binding protein therapeutics | |
| Holt et al. | Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs | |
| Stork et al. | A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G | |
| EP1888641B1 (en) | Serum albumin binding proteins | |
| JP6618463B2 (ja) | 三量体型抗原結合分子 | |
| JP2018512145A5 (enExample) | ||
| US20160376346A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| US10995142B2 (en) | Monoclonal antibody FnAb8 and application thereof | |
| JP2011501951A5 (enExample) | ||
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| CN113365663A (zh) | 单链嵌合多肽和其用途 | |
| Jay et al. | Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair | |
| RU2017134140A (ru) | Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования | |
| JP2017529067A5 (enExample) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| IL258419A (en) | A new polypeptide with affinity for pd-l1 | |
| US20230167200A1 (en) | Platform for constructing multispecific antibody | |
| CN113544144A (zh) | 变体cd80融合蛋白和相关构建体的方法和用途 | |
| JP2020519293A5 (enExample) | ||
| Van Fossen et al. | Nanobody assemblies with fully flexible topology enabled by genetically encoded tetrazine amino acids | |
| JP2019511457A5 (enExample) | ||
| Asano et al. | Anti‐EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half‐life | |
| US20230265191A1 (en) | HIV Specific Binding Molecules | |
| Ge et al. | Chimerism of avian IgY‐scFv and truncated IgG‐Fc: A novel strategy in cross‐species antibody generation and enhancement |